| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24a3910c3989c6e21e2e865c22173c82 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 |
| filingDate |
2021-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69dbac867f870048a899cc02ee13dc55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e0c077138408bb06b96d824714f10b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce6425f79adcb2d1c9b80148ef1ac43a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b954c681c3ab61c0399fdb10108735d7 |
| publicationDate |
2022-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022132201-A2 |
| titleOfInvention |
Pharmaceutical formulations for fusion proteins |
| abstract |
Provided herein are liquid pharmaceutical compositions comprising: a fusion protein that comprises a targeting moiety and an immunomodulatory moiety, wherein: i) said targeting moiety specifically binds human epidermal growth factor receptor (hEGFR); and (ii) said immunomodulatory moiety comprises an amino acid sequence of the extracellular domain of human transforming growth factor-beta receptor H (hTGFpRII); a buffer present at a concentration from about 5 mM to about 30 mM; and a tonifying agent present at a concentration from about 4% w/v to about 10% w/v; wherein said liquid pharmaceutical composition has a pH of from about 5.5 to about 7.0. Also provided herein are methods of preparing liquid pharmaceutical composition comprising fusion proteins, and methods of use in treating cancer. |
| priorityDate |
2020-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |